BPC-157, TB-500 Blend is a dual-peptide formulation supplied exclusively for controlled laboratory research, analytical testing, and in vitro experimentation. It contains chemically synthesized BPC-157 and a thymosin-derived peptide identified as TB-500.
This product is not a drug, dietary supplement, food, cosmetic, or medical product. It is not approved for human or veterinary use.
BPC-157, TB-500 Blend – Research Specifications:
| Specification | Product Information |
|---|---|
| Format | Dual-peptide blend |
| Active Compounds | BPC-157 and TB-500 |
| Available Amounts | 5mg/5mg and 10mg/10mg |
| Source | Chemical synthesis |
| Appearance | Lyophilized powder |
| Purity and Identity | Refer to the lot-specific Certificate of Analysis |
| Analytical Documentation | Batch-specific documentation available through the COA Library |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture |
| Research Classification | For laboratory research use only |
| Restrictions | Not for human or animal consumption, in vivo use, clinical use, diagnostic use, or therapeutic application |
NordSci provides lot-specific analytical documentation to support compound identification, laboratory recordkeeping, internal quality review, and research-material traceability.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
BPC-157, TB-500 Blend is a chemically synthesized, dual-peptide research material containing BPC-157 and TB-500. It is supplied in lyophilized form exclusively for controlled laboratory analysis, method development, peptide characterization, and authorized in vitro research procedures.
The combined format allows both peptide materials to be evaluated within a defined laboratory sample. Researchers should account for the presence of two distinct compounds when selecting analytical methods, establishing controls, interpreting chromatographic data, and documenting experimental variables.
Product identity, purity, and other reported quality parameters are documented on the applicable lot-specific Certificate of Analysis. Researchers should review the COA before incorporating the material into a laboratory protocol.
BPC-157, TB-500 Blend – Research Specifications:
| Product Type | Synthetic peptide blend |
| Active Compounds | BPC-157 and TB-500 |
| Available Amounts | 5mg/5mg and 10mg/10mg |
| Form | Lyophilized powder |
| Source | Chemical synthesis |
| Purity / Identity | Refer to the lot-specific Certificate of Analysis |
| Testing Documentation | Batch-specific analytical documentation available |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, moisture, and unnecessary temperature variation. |
| Intended Application | Controlled laboratory analysis and in vitro research |
| Research Use Only | Not for human or animal consumption, in vivo procedures, clinical use, diagnostic use, or therapeutic application. |
BPC-157 is a synthetic 15-amino-acid peptide identified in laboratory literature as a gastric peptide sequence. TB-500 is a synthetic thymosin-derived peptide used as a research material in peptide-characterization and biochemical pathway studies.
Although both compounds appear in peptide research literature, they are chemically distinct materials. A blended product should not be treated as a single molecular entity. Researchers must consider the identity, concentration, analytical behavior, and stability of each component when establishing controls and evaluating results.
Laboratories requiring an individual peptide instead of a combined material may review BPC-157 or Thymosin Beta-4. These materials should be evaluated separately from the blended formulation because their specifications and analytical profiles may differ.
Important Research Notice: NordSci products include lot-specific analytical documentation. Certificates of Analysis are available to assist with material identification, quality review, laboratory recordkeeping, and study reproducibility.
THIS PRODUCT IS INTENDED EXCLUSIVELY FOR LABORATORY RESEARCH. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR IN VIVO, CLINICAL, DIAGNOSTIC, OR THERAPEUTIC USE.
The blend may be examined using laboratory methods selected to identify and distinguish its individual peptide components. Analytical procedures should be validated for a multi-compound sample rather than assumed to perform identically to methods developed for a single peptide.
Qualified laboratories may use the material when developing or evaluating analytical methods involving chromatography, mass spectrometry, or related peptide-assessment techniques. Method suitability, detection limits, and compound separation should be established within the laboratory.
Controlled in vitro studies may compare the blended material with individually sourced BPC-157 or thymosin-derived research materials. Appropriate negative controls, reference standards, and independently defined endpoints are necessary to distinguish compound-specific observations from blend-related variables.
The dual-peptide format may be incorporated into laboratory designs examining more than one peptide input under controlled conditions. Researchers should document compound concentrations, sample-preparation variables, control groups, analytical methods, and acceptance criteria before beginning an experiment.
BPC-157, TB-500 Blend should be handled only in an appropriately equipped laboratory by qualified research personnel. Maintain the material in its original labeled container, protect it from contamination, and document receipt, storage, transfer, and disposal according to institutional procedures.
Because this product contains two peptide materials, laboratories should confirm that selected analytical methods are suitable for a blended sample. Experimental records should clearly identify the product lot, material amount, storage history, preparation procedure, controls, and analytical instruments used.
Protocol Design Considerations: Multi-compound research can introduce analytical overlap and additional experimental variables. Laboratories should use appropriate reference materials, controls, validated methods, and predefined acceptance criteria to maintain interpretability and reproducibility.
Note: This information is provided solely as a technical reference for qualified laboratory personnel. It does not constitute dosing, administration, medical, veterinary, diagnostic, or therapeutic guidance.
A lot-specific Certificate of Analysis is available for BPC-157, TB-500 Blend. The COA records the analytical information reported for the applicable production lot and may be used for material verification, procurement documentation, internal quality review, and laboratory recordkeeping.
Researchers should review the applicable COA before use and retain it with the corresponding laboratory records. Results from one lot should not be assumed to represent another lot.
NordSci Peptides supplies BPC-157, TB-500 Blend exclusively as a laboratory research material. Each vial is labeled for research use, and lot-specific analytical documentation is available through the COA Library.
Qualified laboratories sourcing this material should prioritize accurate compound labeling, lot-specific traceability, Certificate of Analysis availability, documented storage requirements, compatibility with established analytical methods, and compliance with institutional and jurisdictional restrictions.
IMPORTANT: BPC-157, TB-500 Blend is not a drug, dietary supplement, food, cosmetic, or medical product. It is not approved for human consumption, animal consumption, in vivo procedures, clinical use, diagnosis, treatment, cure, mitigation, or prevention of any disease or condition. No dosing, administration, injection, or application guidance is provided.
